Clinical Trial Update: Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age [Phase 1, Phase 2]

View source ↗

Summary

This update covers a Phase 1/2 clinical trial evaluating the safety, reactogenicity, and immunogenicity of Moderna's mRNA vaccines mRNA-1403 and mRNA-1405 to pr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Norovirus Acute Gastroenteritis

Drugs mentioned

• mRNA-1403
• mRNA-1405

Snippet

Sponsor: ModernaTX, Inc. | Conditions: Norovirus Acute Gastroenteritis | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING